| Literature DB >> 22384228 |
RongKai Zhang1, Hang Fang, YuXian Chen, Jun Shen, HuaDing Lu, Chun Zeng, JianHua Ren, Hua Zeng, Zhifu Li, ShaoMing Chen, DaoZhang Cai, Qing Zhao.
Abstract
Osteoarthritis (OA) is a degenerative joint disease that affects both cartilage and bone. A better understanding of the early molecular changes in subchondral bone may help elucidate the pathogenesis of OA. We used microarray technology to investigate the time course of molecular changes in the subchondral bone in the early stages of experimental osteoarthritis in a rat model. We identified 2,234 differentially expressed (DE) genes at 1 week, 1,944 at 2 weeks and 1,517 at 4 weeks post-surgery. Further analyses of the dysregulated genes indicated that the events underlying subchondral bone remodeling occurred sequentially and in a time-dependent manner at the gene expression level. Some of the identified dysregulated genes that were identified have suspected roles in bone development or remodeling; these genes include Alp, Igf1, Tgf β1, Postn, Mmp3, Tnfsf11, Acp5, Bmp5, Aspn and Ihh. The differences in the expression of these genes were confirmed by real-time PCR, and the results indicated that our microarray data accurately reflected gene expression patterns characteristic of early OA. To validate the results of our microarray analysis at the protein level, immunohistochemistry staining was used to investigate the expression of Mmp3 and Aspn protein in tissue sections. These analyses indicate that Mmp3 protein expression completely matched the results of both the microarray and real-time PCR analyses; however, Aspn protein expression was not observed to differ at any time. In summary, our study demonstrated a simple method of separation of subchondral bone sample from the knee joint of rat, which can effectively avoid bone RNA degradation. These findings also revealed the gene expression profiles of subchondral bone in the rat OA model at multiple time points post-surgery and identified important DE genes with known or suspected roles in bone development or remodeling. These genes may be novel diagnostic markers or therapeutic targets for OA.Entities:
Mesh:
Year: 2012 PMID: 22384228 PMCID: PMC3288107 DOI: 10.1371/journal.pone.0032356
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Macroscopic analysis of femoral condyles in a rat model of osteoarthritis.
No detectable macroscopic surface changes were observed in the femoral condyle (A) of E-group rats at 1 week post-surgery. At 2 weeks post-surgery, the local medial femoral condyle of the distal femur exhibited a slightly rough articular surface (B, arrow). Significant roughness of the articular surface was observed both on the medial and lateral femoral condyle (C, arrow) at 4 weeks post-surgery. The knee joints (D, E, F) of the S-group exhibited a normal articular surface at all time points following the surgery.
Figure 2Histologic analysis of cartilage degradation induced by medial meniscectomy and medial collateral ligament (MCL) transection, evaluated by section staining with safranin-O and rapid green.
The sections were stained with safranin-O (red stain) for glycosaminoglycans, rapid green for bone and fibrous tissue (green stain), and counterstained with Mayer's hematoxylin for nuclei (blue). A slight decrease in glycosaminoglycan staining at 1 week post-surgery is shown (A, arrow). A loss of superficial cartilage and focal fibrillation of the articular surface at 2 weeks post-surgery was seen (B, arrow). A focal loss of chondrocytes and exposure of subchondral bone wear observed at 4 weeks post-surgery (C, arrow). A healthy articular surface was observed throughout the study (D, E, F). Each of the above images was captured from representative locations from sections of femur condyles and is shown at the same magnification. The scale bar represents 200 µm.
Figure 3Integrated analyses of the DE genes in the subchondral bone of E-Group versus S-group samples.
The number of DE genes at each time point is shown in A. DE genes were classified according to their differential expression levels with a minimum of 2-fold, 3-fold, 4-fold and 6-fold differences (B). Venn diagram depicting the overlap of dysregulated genes at three time points post-surgery (C). The expression patterns of 112 genes that were differentially expressed at all three time points are shown in D. Dendrogram of the unsupervised hierarchical clustering analysis of the E-Group and S-group samples at each time point is shown in E. The clustering was performed based on DE genes of the E-group versus the S-group at each time point. Euclidean distances were used to measure the similarities between the expression profiles of the samples.
Representative DE genes with known or suspected roles in osteoclast differentiation and function [11], [32]–[34], [36], [38].
| Fold-change | |||||
| Genebank | Symbol | Description | 1W | 2W | 4W |
| NM_019144 | Acp5 | Acid phosphatase 5, tartrate resistant | 2.42 | ||
| NM_031560 | Ctsk | Cathepsin K | 4.18 | ||
| NM_023981 | Csf1 | Colony stimulating factor 1 (macrophage) | −4.39 | ||
| NM_053384 | Ihh | Indian hedgehog | 3.41 | 2.32 | |
| NM_148892 | Ostf1 | Osteoclast stimulating factor 1 | −4.37 | ||
| XM_001072313 | Mmp1b | Matrix metalloproteinase 1b (interstitial collagenase) | 3.39 | ||
| NM_031054 | Mmp2 | Matrix metallopeptidase 2 | 3.74 | ||
| NM_133523 | Mmp3 | Matrix metallopeptidase 3 | 6.62 | 5.51 | |
| NM_053963 | Mmp12 | Matrix metallopeptidase 12 | 4.26 | ||
| NM_133530 | Mmp 13 | Matrix metallopeptidase 13 | 2.83 | ||
| NM_031056 | Mmp 14 | Matrix metallopeptidase 14 | 2.61 | ||
| NM_080776 | Mmp 16 | Matrix metallopeptidase 16 | 2.12 | ||
| NM_053606 | Mmp23 | Matrix metallopeptidase 23 | 2.14 | ||
| NM_031757 | Mmp24 | Matrix metallopeptidase 24 | 2.31 | ||
| TC609946 | TIMP1 | Metalloproteinase inhibitor 1 precursor, partial (70%) | 2.52 | ||
| NM_057149 | Tnfsf11(RANKL) | Tumor necrosis factor (ligand) superfamily, member 11 | 2.81 | ||
| NM_012870 | Tnfrsf11b (OPG) | Tumor necrosis factor receptor superfamily, member 11b | 2.12 | ||
* = P<0.05,
** = P<0.01, - = down-regulated (E-Group versus S-Group samples).
Representative DE genes with known or suspected roles in osteoblast differentiation and function [3], [5], [6], [11], [14], [16], [19].
| Fold-change | |||||
| Genebank | Symbol | Description | 1W | 2W | 4W |
| NM_013059 | Alp | Alkaline phosphatase,liver/bone/kidney | −2.93 | −3.55 | |
| NM_133569 | Angptl2 | angiopoietin-like 2 | 2.19 | ||
| NP_001102853 | Angptl1 | angiopoietin-like 1 | 4.57 | 2.63 | |
| NM_001013191 | Cbfβ | Core-binding factor, beta subunit | −3.92 | ||
| NM_053304 | Col-1α1 | Collagen, type I, alpha 1 | 3.19 | ||
| NM_053356 | Col-1α2 | Collagen, type I, alpha 2 | 4.06 | ||
| NM_032085 | Col-3α1 | Collagen, type III, alpha 1 | 5.00 | 3.32 | |
| NM_001135009 | Col-4α1 | Collagen, type IV, alpha 1 | 2.04 | −4.45 | |
| NM_031622 | Mapk6 | Mitogen-activated protein kinase 6 | 2.21 | ||
| NM_178866 | Igf1 | insulin-like growth factor 1, transcript variant 2 | 2.30 | ||
| NM_001082479 | Igf1 | Insulin-like growth factor 1, transcript variant 4 | 2.24 | ||
| NM_053329 | Igfals | Insulin-like growth factor binding protein, acid labile subunit | 2.02 | 2.20 | |
| NM_013144 | Igfbp1 | Insulin-like growth factor binding protein 1 | −2.63 | ||
| NM_001012118 | Osr2 | Odd-skipped related 2 (Drosophila) | 2.75 | 3.27 | |
| NM_001108550 | Postn | Periostin, osteoblast specific factor | 6.34 | 3.07 | |
| NM_017044 | Pth | Parathyroid hormone | 2.46 | ||
| NM_012636 | Pthlh | Parathyroid hormone-like hormone | 6.47 | ||
| NM_020073 | Pth1r | Parathyroid hormone 1 receptor | 2.20 | ||
* = P<0.05,
** = P<0.01, - = down-regulated (E-Group versus S-Group samples).
Genes with known or suspected roles in bone development or remodeling [3], [35], [36].
| Fold-change | |||||
| Genebank | Symbol | Description | 1W | 2W | 4W |
| NM_198761 | Adamts5 | ADAM metallopeptidase with thrombospondin type 1 motif, 5 | 2.13 | ||
| NM_001014008 | Aspn | Asporin | 6.18 | 4.26 | |
| NM_031323 | Bmp1 | Bone morphogenetic protein 1 | 2.72 | ||
| NM_017105 | Bmp3 | Bone morphogenetic protein 3 | 2.25 | ||
| NM_012827 | Bmp4 | Bone m orphogenetic protein 4 | 2.24 | ||
| NM_001108168 | Bmp5 | Bone morphogenetic protein 5 | 2.19 | 2.43 | |
| NM_030849 | Bmpr1a | Bone morphogenetic protein receptor, type IA | 2.19 | ||
| NM_013146 | Cald1 | Caldesmon 1 | 2.34 | ||
| NM_012929 | Col-2α1 | Collagen, type II, alpha 1 | 2.35 | ||
| NM_134452 | Col-5α1 | Collagen, type V, alpha 1 | 3.91 | ||
| NM_053488 | Col-5α2 | Collagen, type V, alpha 2 | 4.17 | ||
| NM_021760 | Col-5α3 | Collagen, type V, alpha 3 | 2.08 | ||
| NM_001100741 | Col-6α2 | Collagen, type VI, alpha 2 | 2.21 | ||
| NM_001107100 | Col-8α1 | Collagen, type VIII, alpha 1 | 2.35 | ||
| NM_001100842 | Col-9α1 | Collagen, type IX, alpha 1 | 2.07 | ||
| NM_001108675 | Col-9α2 | Collagen, type IX, alpha 2 | 2.90 | ||
| NM_001108611 | Co-l9α3 | Procollagen, type IX, alpha 3 | 2.96 | ||
| NM_212528 | Col-11α2 | Collagen, type XI, alpha 2 | 2.64 | ||
| NM_001015033 | Col-16α1 | Collagen, type XVI, alpha 1 | 3.02 | ||
| NM_053489 | Col-18α1 | Collagen, type XVIII, alpha 1 | 2.83 | ||
| NM_198747 | Col-27α1 | Collagen, type XXVII, alpha 1 | 2.64 | ||
| NM_053357 | Ctnn-β1 | Catenin (cadherin associated protein), beta 1 | 2.27 | ||
| NM_031764 | Ddr2 | Discoidin domain receptor tyrosine kinase 2 | 2.05 | ||
| NM_012712 | Fgfr2 | Fibroblast growth factor receptor 2, transcript variant a | −3.82 | ||
| NM_053429 | Fgfr3 | Fibroblast growth factor receptor 3 | 2.49 | ||
| NM_001109165 | Fgfbp3 | Fibroblast growth factor binding protein 3 | 2.11 | 2.48 | 3.04 |
| NM_138850 | Fap | Fibroblast activation protein, alpha | 2.16 | ||
| NM_053428 | Fgf13 | Fibroblast growth factor 13 | 2.51 | ||
| NM_053708 | Gbx2 | Gastrulation brain homeobox 2 | −3.60 | 2.49 | |
| NM_024352 | Mst1 | Macrophage stimulating 1 (hepatocyte growth factor-like) | 2.07 | ||
| NM_198768 | Igsf10 | Immunoglobulin superfamily, member 10 | 2.89 | ||
| NM_053470 | Runx2 | Runt related transcription factor 2 (Runx2) | −2.35 | ||
| NM_130425 | Runx3 | Runt-related transcription factor 3 (Runx3) | −2.86 | ||
| NM_013082 | Sdc2 | Syndecan 2 | 2.55 | 2.18 | |
| NM_001100700 | Sfrp2 | Secreted frizzled-related protein 2 | 3.08 | 2.89 | |
| NM_021578 | Tgf-β1 | Transforming growth factor, beta 1 | −3.46 | ||
| NM_031716 | Wisp1 | WNT1 inducible signaling pathway protein 1 | 2.54 | ||
| NM_001170483 | Wisp3 | WNT1 inducible signaling pathway protein 3 | −2.96 | −3.61 | |
* = P<0.05,
** = P<0.01, - = down-regulated (E-Group versus S-Group samples).
DE genes encoding C-C, C-X-C, C-X3-C chemokines and their receptors [44]–[51].
| Fold-change | |||||
| Genebank | Symbol | Description | 1W | 2W | 4W |
| AF079313 | Ccl2 (MCP-1) | Monocyte chemoattractant protein-1 gene, 5′ flanking sequence | −5.71 | −3.07 | |
| NM_013025 | Ccl3 (MIP-1α) | Chemokine (C-C motif) ligand 3 | −2.28 | ||
| NM_053858 | Ccl4 (MIP-1β) | Chemokine (C-C motif) ligand 4 | −4.08 | ||
| NM_001007612 | Ccl7 (MCP-3) | Chemokine (C-C motif) ligand 7 | 2.79 | 2.38 | |
| NM_019205 | Ccl11 | Chemokine (C-C motif) ligand 11 | −2.05 | ||
| NM_001108661 | Ccl19 | Chemokine (C-C motif) ligand 19 | −4.52 | ||
| NM_145672 | Cxcl9 | Chemokine (C-X-C motif) ligand 9 | 11.37 | - | |
| NM_139089 | Cxcl10 | Chemokine (C-X-C motif) ligand10 | −12.08 | ||
| NM_182952 | Cxcl11 | Chemokine (C-X-C motif) ligand11 | −9.18 | ||
| NM_001017496 | Cxcl13 | Chemokine (C-X-C motif) ligand13 | −3.28 | ||
| NM_134455 | Cx3cl1 | Chemokine (C-X3-C motif) ligand 1 | −2.30 | ||
| NM_053960 | Ccr5 | Chemokine (C-C motif) receptor 5 | −2.00 | ||
| NM_172329 | Ccr9 | Chemokine (C-C motif) receptor 9 | 2.19 | ||
| NM_022218 | Cmklr1 | Chemokine-like receptor 1 | −2.68 | ||
* = P<0.05,
** = P<0.01, - = down-regulated (E-Group versus S-Group samples).
Inflammatory DE genes encoding cytokines and their receptors [24]–[26], [29], [31].
| Fold-change | |||||
| Genebank | Symbol | Description | 1W | 2W | 4W |
| NM_001108570 | IL1f8 | Interleukin 1 family, member 8 | 2.51 | 2.08 | |
| NM_013037 | IL1rl1 | Interleukin 1 receptor-like 1, transcript variant 1, | 2.03 | ||
| NM_013195 | IL2rβ | Interleukin 2 receptor, beta | −2.67 | ||
| NM_001106418 | IL7r | Interleukin 7 receptor | −2.76 | ||
| NM_012854 | IL10 | Interleukin 10 | −2.00 | ||
| NM_145789 | IL13rα1 | Interleukin 13 receptor, alpha 1 | 2.08 | ||
| NM_019165 | IL18 | Interleukin 18 | −2.74 | ||
| NM_053374 | IL18bp | Interleukin 18 binding protein | −2.35 | ||
| NM_001106667 | Ifn-α4 | Interferon, alpha 4 | −2.03 | −2.45 | |
| NM_138880 | Ifn-γ | Interferon gamma | −2.73 | ||
| NM_012855 | Jak3 | Janus kinase 3 | −2.33 | −2.67 | |
| NM_032612 | Stat1 | Signal transducer and activator of transcription 1, transcript variant alpha | −2.38 | ||
| NM_012747 | Stat3 | Signal transducer and activator of transcription 3 | −4.42 | ||
| NM_053565 | Socs3 | Suppressor of cytokine signaling 3 | −2.04 | ||
| NM_001025773 | Tnfrsf9 | Tumor necrosis factor receptor superfamily, member 9 | −2.66 | ||
| NM_181384 | Tnfsf9 | Tumor necrosis factor (ligand) superfamily, member 9 | 2.17 | 2.25 | |
| NM_001034947 | Ttrap | Traf and Tnf receptor associated protein | −2.25 | ||
| NM_031836 | Vegfa | Vascular endothelial growth factor A, transcript variant 1 | −2.71 | ||
* = P<0.05,
** = P<0.01, - = down-regulated (E-Group versus S-Group samples).
Figure 4The distribution of the DE genes at each post-surgical time point is described based on the three gene ontology categories and the numbers of DE genes in the first four gene functional classifications of each gene ontology category.
A. The distribution of DE genes was similar among the three gene ontology categories at each post-surgical time point. B. The functional classifications of the dysregulated genes involved in the biological processes category and the numbers of dysregulated genes in the first four functional classifications at each post-surgical time point. C. The functional classifications of the dysregulated genes involved in the cellular component category and the numbers of dysregulated genes in the first four functional classifications at each post-surgical time point. D. The functional classifications of the dysregulated genes involved in the molecular function category and the numbers of dysregulated genes in the first four functional classifications at each post-surgical time point.
Representative biological processes enriched with DE genes identified at 1 week post-surgery.
| GOID | GO term | Number of genes | Fisher-Pvalue |
| GO:0032501 |
| 246 | 0.0057 |
| GO:0032502 |
| 213 | 0.00009 |
| GO:0007275 |
| 198 | 0.00003 |
| GO:0048856 |
| 180 | 0.00012 |
| GO:0009605 | response to external stimulus | 64 | 0.00284 |
| GO:0009611 | response to wounding | 56 | 0.00141 |
| GO:0001568 | blood vessel development | 41 | 0 |
| GO:0048583 | regulation of response to stimulus | 40 | 0.03473 |
| GO:0001501 | skeletal system development | 38 | 0.00001 |
| GO:0048545 | response to steroid hormone stimulus | 38 | 0.02035 |
| GO:0001944 | vasculature development | 42 | 0 |
| GO:0048514 | blood vessel morphogenesis | 33 | 0.00001 |
| GO:0042060 | wound healing | 30 | 0.00015 |
| GO:0060348 | bone development | 27 | 0.00004 |
| GO:0048584 | positive regulation of response to stimulus | 25 | 0.01695 |
| GO:0001503 | ossification | 23 | 0.00071 |
| GO:0030198 | extracellular matrix organization | 23 | 0 |
| GO:0006816 | calcium ion transport | 19 | 0.03767 |
| GO:0032101 | regulation of response to external stimulus | 19 | 0.04736 |
| GO:0034097 | response to cytokine stimulus | 17 | 0.02595 |
| GO:0006935 | chemotaxis | 16 | 0.00095 |
| GO:0016055 | Wnt receptor signaling pathway | 14 | 0.03239 |
| GO:0048705 | skeletal system morphogenesis | 14 | 0.00029 |
| GO:0051216 | cartilage development | 14 | 0.0005 |
| GO:0009612 | response to mechanical stimulus | 12 | 0.02122 |
| GO:0032103 | positive regulation of response to external stimulus | 12 | 0.00556 |
| GO:0051924 | regulation of calcium ion transport | 11 | 0.01044 |
| GO:0001649 | osteoblast differentiation | 10 | 0.03949 |
| GO:0030199 | collagen fibril organization | 9 | 0 |
| GO:0060349 | bone morphogenesis | 9 | 0.00001 |
| GO:0032963 | collagen metabolic process | 8 | 0.00368 |
| GO:0002062 | chondrocyte differentiation | 7 | 0.00254 |
| GO:0002541 | activation of plasma proteins involved in acute inflammatory response | 7 | 0.00649 |
| GO:0051928 | positive regulation of calcium ion transport | 6 | 0.04434 |
| GO:0060350 | endochondral bone morphogenesis | 6 | 0.0001 |
| GO:0001569 | patterning of blood vessels | 5 | 0.00279 |
| GO:0045669 | positive regulation of osteoblast differentiation | 5 | 0.03069 |
| GO:0061035 | regulation of cartilage development | 5 | 0.00067 |
| GO:0030574 | collagen catabolic process | 4 | 0.01807 |
| GO:0032964 | collagen biosynthetic process | 4 | 0.03775 |
| GO:0050918 | positive chemotaxis | 4 | 0.03775 |
| GO:0050926 | regulation of positive chemotaxis | 4 | 0.02368 |
| GO:0050927 | positive regulation of positive chemotaxis | 4 | 0.02368 |
| GO:0060351 | cartilage development involved in endochondral bone morphogenesis | 4 | 0.00022 |
| GO:0071345 | cellular response to cytokine stimulus | 4 | 0.03775 |
| GO:0001958 | endochondral ossification | 3 | 0.01527 |
*GO term in bold are the four most enrich biological processes.
Representative biological processes enriched with DE genes identified at 2 weeks post-surgery.
| GOID | GO term | Number of genes | Fisher-Pvalue |
| GO:0032501 |
| 173 | 0.04764 |
| GO:0032502 |
| 145 | 0.01263 |
| GO:0007275 |
| 135 | 0.00601 |
| GO:0048856 |
| 126 | 0.00412 |
| GO:0048545 | response to steroid hormone stimulus | 28 | 0.03465 |
| GO:0001501 | skeletal system development | 23 | 0.00673 |
| GO:0001568 | blood vessel development | 20 | 0.02913 |
| GO:0001944 | vasculature development | 20 | 0.03454 |
| GO:0042060 | wound healing | 18 | 0.02142 |
| GO:0043627 | response to estrogen stimulus | 17 | 0.01539 |
| GO:0006816 | calcium ion transport | 15 | 0.03209 |
| GO:0034097 | response to cytokine stimulus | 15 | 0.0068 |
| GO:0060348 | bone development | 15 | 0.02454 |
| GO:0030198 | extracellular matrix organization | 12 | 0.00007 |
| GO:0032355 | response to estradiol stimulus | 12 | 0.01553 |
| GO:0051216 | cartilage development | 11 | 0.00111 |
| GO:0048705 | skeletal system morphogenesis | 10 | 0.00265 |
| GO:0051924 | regulation of calcium ion transport | 9 | 0.00964 |
| GO:0043406 | positive regulation of MAP kinase activity | 8 | 0.04488 |
| GO:0048706 | embryonic skeletal system development | 7 | 0.00989 |
| GO:0000187 | activation of MAPK activity | 6 | 0.045 |
| GO:0048704 | embryonic skeletal system morphogenesis | 6 | 0.01051 |
| GO:0060349 | bone morphogenesis | 5 | 0.00428 |
| GO:0051926 | negative regulation of calcium ion transport | 4 | 0.00775 |
| GO:0030199 | collagen fibril organization | 3 | 0.03856 |
| GO:0001569 | patterning of blood vessels | 3 | 0.03856 |
| GO:0030513 | positive regulation of BMP signaling pathway | 2 | 0.04539 |
| GO:0033687 | osteoblast proliferation | 2 | 0.03149 |
| GO:0051280 | negative regulation of release of sequestered calcium ion into cytosol | 2 | 0.00355 |
| GO:0010523 | negative regulation of calcium ion transport into cytosol | 2 | 0.01024 |
| GO:0090090 | negative regulation of Wnt receptor signaling pathway through beta-catenin | 2 | 0.03149 |
*GO terms in bold are the four most enriched biological processes.
Representative biological processes enriched with DE genes identified at 4 weeks post-surgery.
| GOID | GO term | Number of genes | Fisher-Pvalue |
| GO:0010467 |
| 98 | 0.02722 |
| GO:0006412 |
| 41 | 0 |
| GO:0034621 |
| 18 | 0.01368 |
| GO:0006325 |
| 13 | 0.04592 |
| GO:0060348 | bone development | 12 | 0.02852 |
| GO:0046887 | positive regulation of hormone secretion | 6 | 0.02371 |
| GO:0010816 | calcitonin catabolic process | 1 | 0.04494 |
*GO terms in bold are the four most enriched biological processes.
Figure 5Gene expression patterns of Alp, Igf1, Tgf-β1 and Postn (genes involved in osteoblasts differentiation and function), Mmp3, Tnfsf11 and Acp5 (genes involved in osteoclasts differentiation and function), and Bmp5, Aspn, Ihh (known OA-related genes), evaluated by real-time polymerase chain reaction (PCR).
The expression profiles of each gene matched the tested probes at a minimum of two time points. A similar degree of variability was observed at other time points in the real-time PCR results without statistically significant differences between groups. The values are the mean and SEM of the gene expression levels in 5 animals (separate from the animals used for microarray analyses), as determined by ΔCt analysis, normalized to GAPDH expression, and relative to the expression levels of sham-operated controls. * p<0.05, ** p<0.01 (versus sham-operated controls).
Figure 6Evaluation of the expression levels of Mmp3 in the subchondral bone of the E-Group and the S-Group using immunohistochemistry staining.
The antibody against Mmp3 was used to assess the spatial and temporal expression of the protein by colorimetric detection (brown precipitate). The mononuclear cells of both groups appeared positive for the same levels of Mmp3 at 1, 2 and 4 weeks post-surgery. The polynuclear giant cells in the subchondral bone of the E-Group expressed Mmp3 in their cytoplasm 1 and 2 weeks post-surgery, but not at 4 weeks, wheras those of the S-Group appeared negative at all three time points post-surgery. Specifically, obvious differences were discovered in the E-Group between 1 week and 2 weeks post-surgery, including stronger positive signals and more positive cells at 1 week compared with 2 weeks post-surgery. All sections were counterstained with hematoxylin (blue stain). The scale bars for 10X, 40X and Cell-view are 200 µm, 50 µm, and 50 µm respectively.
Primers of real-time PCR target genes and internal control GAPDH.
| GenBank Accession | Symbol | F-Primer (5′-3′) | R-Primer (5′-3′) |
| NM_017008.3 | GAPDH |
|
|
| NM_133523.2 | Mmp3 |
|
|
| NM_019144.1 | Acp5 |
|
|
| NM_057149 | Tnfsf11 |
|
|
| NM_013059 | Alp |
|
|
| NM_001108550.1 | Postn |
|
|
| NM_001082479.1 | Igf1 |
|
|
| NM_053384 | Ihh |
|
|
| NM_021578 | Tgf-β1 |
|
|
| NM_001108168 | Bmp5 |
|
|
| NM_001014008 | Aspn |
|
|
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Mmp3, matrix metallopeptidase 3; Acp5, acid phosphatase 5 tartrate resistant; Tnfsf11, tumor necrosis factor (ligand) superfamily, member 11; Alp, alkaline phosphatase; Postn, periostin osteoblast specific factor; IGF1, insulin-like growth factor 1; Ihh, Indian hedgehog; Tgf-β1, transforming growth factor beta 1; Bmp5, bone morphogenetic protein 5; Aspn, asporin.